Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Express Pharma
Maharashtra FDA cancels Cipla C&F drug sale licences in Pune
The action follows inspections in June 2026 involving Reactin Plus Tablets, a Schedule H prescription medicine. The post Maharashtra FDA cancels Cipla C&F drug sale licences in Pune appeared first on Express Pharma.
Read Full Article
Pharma Tech
Myasthenia gravis market to reach $13.0bn across 7MM by 2034
The myasthenia gravis (MG) market across the 7MM is poised to grow at a CAGR of 11.1% from $4.5bn in 2024 to $13.0bn in 2034.
Read Full Article
Pharma Tech
Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction
The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.
Read Full Article
PharmaShots
Top 20 Monoclonal Antibodies of 2026Â
Shots: 20. Proprietary Name: Taltz Non-Proprietary Name: Ixekizumab Company: Eli Lilly First Approved: US (Mar 22, 2016), EU (Apr 25, 2016)  Total Revenue: $3.56B 19. Proprietary Name: Perjeta Non-Proprietary Name: Pertuzumab Company: Roche First Approved: US (Jun 08, 2012), EU (Mar 04, 2013)  Total Revenue: $3.75B 18. Proprietary Name: Prolia Non-Proprietary Name: Denosumab Company: Amgen First Approved: US (Jun 01, 2010), EU (May 26, 2010)  Total Revenue: $4.41B 17. Proprietary… The post Top 20 Monoclonal Antibodies of 2026 appeared first on PharmaShots.
Read Full Article
Pharma Tech
FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first
Priovant is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty pharmacies.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
Express Pharma
Aug 29, 2026, 6:41 AM
Maharashtra FDA cancels Cipla C&F drug sale licences in Pune
The action follows inspections in June 2026 involving Reactin Plus Tablets, a Schedule H prescription medicine. The post Maharashtra FDA cancels Cipla C&F drug sale licences in Pune appeared first on Express Pharma.
Pharma Tech
Aug 28, 2026, 3:36 PM
Myasthenia gravis market to reach $13.0bn across 7MM by 2034
The myasthenia gravis (MG) market across the 7MM is poised to grow at a CAGR of 11.1% from $4.5bn in 2024 to $13.0bn in 2034.
Pharma Tech
Aug 28, 2026, 2:15 PM
Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction
The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.
PharmaShots
Aug 28, 2026, 1:30 PM
Top 20 Monoclonal Antibodies of 2026Â
Shots: 20. Proprietary Name: Taltz Non-Proprietary Name: Ixekizumab Company: Eli Lilly First Approved: US (Mar 22, 2016), EU (Apr 25, 2016)  Total Revenue: $3.56B 19. Proprietary Name: Perjeta Non-Proprietary Name: Pertuzumab Company: Roche First Approved: US (Jun 08, 2012), EU (Mar 04, 2013)  Total Revenue: $3.75B 18. Proprietary Name: Prolia Non-Proprietary Name: Denosumab Company: Amgen First Approved: US (Jun 01, 2010), EU (May 26, 2010)  Total Revenue: $4.41B 17. Proprietary… The post Top 20 Monoclonal Antibodies of 2026 appeared first on PharmaShots.
PharmaShots
Aug 28, 2026, 12:30 PM
SOTIO Biotech Receives FDA Fast Track Designation for SOT106 to Treat Soft Tissue Sarcoma
Shots: Ref: Globenewswire |  Image: SOTIO Biotech | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post SOTIO Biotech Receives FDA Fast Track Designation for SOT106 to Treat Soft Tissue Sarcoma appeared first on PharmaShots.
PharmaShots
Aug 28, 2026, 11:30 AM
Daiichi Sankyo Doses First Patient in the P-I Trial with DS1025 for Advanced Solid Tumors
Shots: Ref: Businesswire |  Image: Daiichi Sankyo | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Daiichi Sankyo Doses First Patient in the P-I Trial with DS1025 for Advanced Solid Tumors appeared first on PharmaShots.
News
Latest industry coverage
Google News
Aug 30, 2026, 3:45 AM
CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data - simplywall.st
CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data  simplywall.st
Google News
Aug 30, 2026, 3:40 AM
Agilent delivering science at digital scale - BioSpectrum India
Agilent delivering science at digital scale  BioSpectrum India
Google News
Aug 30, 2026, 3:04 AM
India-Argentina Deepen Trade Ties, Explore Lithium And Pharma Access - Sarkaritel.com
India-Argentina Deepen Trade Ties, Explore Lithium And Pharma Access  Sarkaritel.com
Google News
Aug 30, 2026, 12:40 AM
3 Things That Matter Most for Eli Lilly Now - The Motley Fool
3 Things That Matter Most for Eli Lilly Now  The Motley Fool
Google News
Aug 30, 2026, 12:35 AM
3 Things That Matter Most for Eli Lilly Now - AOL.com
3 Things That Matter Most for Eli Lilly Now  AOL.com
Google News
Aug 30, 2026, 12:30 AM
Corporate Actions This Week: Coal India, ONGC, Glenmark Pharma, GAIL, Nirlon — Check Full List Here - NDTV Profit
Corporate Actions This Week: Coal India, ONGC, Glenmark Pharma, GAIL, Nirlon — Check Full List Here  NDTV Profit
Google News
Aug 29, 2026, 11:50 PM
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? - The Motley Fool
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?  The Motley Fool
Google News
Aug 29, 2026, 11:28 PM
Is Crinetics Pharmaceuticals (CRNX) Fully Priced After A 3.9x Run? - simplywall.st
Is Crinetics Pharmaceuticals (CRNX) Fully Priced After A 3.9x Run?  simplywall.st
Google News
Aug 29, 2026, 9:46 PM
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed? - simplywall.st
Amylyx Pharmaceuticals (AMLX) Is Down 10.1% After Strong Phase 3 Avexitide Data And $500M Equity Raise – Has The Bull Case Changed?  simplywall.st
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer